Fibrinogen (Fbg) levels and extent of fibrin polymerization have been associated with various pathological conditions such as cardiovascular disease, arteriosclerosis, and coagulation disorders. Activated factor XIII (FXIIIa) introduces γ-glutamyl-ε-lysinyl isopeptide bonds between reactive glutamines and lysines in the fibrin network to form a blood clot resistant to fibrinolysis. FXIIIa crosslinks the γ-chains and at multiple sites in the αC region of Fbg. Fbg αC contains a FXIII binding site involving αC (389–402) that is located near three glutamines whose reactivities rank Q237 >> Q366 ≈ Q328. Mass spectrometry and two-dimensional heteronuclear single-quantum correlation nuclear magnetic resonance assays were used to probe the anchoring role that αC E396 may play in controlling FXIII function and characterize the effects of Q237 on the reactivities of Q328 and Q366. Studies with αC (233–425) revealed that the E396A mutation does not prevent the transglutaminase function of FXIII A2 or A2B2. Other residues must play a compensatory role in targeting FXIII to αC. Unlike full Fbg, Fbg αC (233–425) did not promote thrombin cleavage of FXIII, an event contributing to activation. With the αC (233–425) E396A mutant, Q237 exhibited slower reactivities compared with αC wild-type (WT) consistent with difficulties in directing this N-terminal segment toward an anchored FXIII interacting at a weaker binding region. Q328 and Q366 became less reactive when Q237 was replaced with inactive N237. Q237 crosslinking is proposed to promote targeting of Q328 and Q366 to the FXIII active site. FXIII thus uses Fbg αC anchoring sites and distinct Q environments to regulate substrate specificity.
Keywords
fibrinogen αC -
factor XIII -
coagulation -
mass spectrometry -
nuclear magnetic resonance
Authors' Contributions
K.N.M., D.W.D., M.L.M., and M.C.M. designed the research. K.N.M., L.J.W., C.A.S., M.M.H., and D.W.D. performed the experiments and analyzed the data. K.N.M., M.L.M., and M.C.M. critically evaluated the results and wrote the manuscript. All authors approved the final manuscript and figures.
6
Yang Z,
Mochalkin I,
Veerapandian L,
Riley M,
Doolittle RF.
Crystal structure of native chicken fibrinogen at 5.5-A resolution. Proc Natl Acad Sci U S A 2000; 97 (08) 3907-3912
8
Muszbek L,
Bereczky Z,
Bagoly Z,
Komáromi I,
Katona É.
Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91 (03) 931-972
11
Standeven KF,
Carter AM,
Grant PJ.
, et al. Functional analysis of fibrin gamma-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110 (03) 902-907
14
Byrnes JR,
Wilson C,
Boutelle AM.
, et al. The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits. Blood 2016; 128 (15) 1969-1978
15
Lee KN,
Lee CS,
Tae WC,
Jackson KW,
Christiansen VJ,
McKee PA.
Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000; 275 (48) 37382-37389
17
Duval C,
Allan P,
Connell SD,
Ridger VC,
Philippou H,
Ariëns RA.
Roles of fibrin α- and γ-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111 (05) 842-850
19
Protopopova AD,
Litvinov RI,
Galanakis DK.
, et al. Morphometric characterization of fibrinogen's αC regions and their role in fibrin self-assembly and molecular organization. Nanoscale 2017; 9 (36) 13707-13716
20
Byrnes JR,
Duval C,
Wang Y.
, et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015; 126 (16) 1940-1948
21
Aleman MM,
Byrnes JR,
Wang JG.
, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124 (08) 3590-3600
25
Smith KA,
Pease RJ,
Avery CA.
, et al. The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. Blood 2013; 121 (11) 2117-2126
26
Doolittle RF,
Cassman KG,
Cottrell BA,
Friezner SJ.
Amino acid sequence studies on the alpha chain of human fibrinogen. Isolation and characterization of two linked alpha-chained cyanogen bromide fragments from fully cross-linked fibrin. Biochemistry 1977; 16 (08) 1715-1719
27
Kárpáti L,
Penke B,
Katona E,
Balogh I,
Vámosi G,
Muszbek L.
A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000; 46 (12) 1946-1955
29
Mouapi KN,
Bell JD,
Smith KA,
Ariëns RA,
Philippou H,
Maurer MC.
Ranking reactive glutamines in the fibrinogen αC region that are targeted by blood coagulant factor XIII. Blood 2016; 127 (18) 2241-2248
30
Matsuka YV,
Medved LV,
Migliorini MM,
Ingham KC.
Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Biochemistry 1996; 35 (18) 5810-5816
31
Schwartz ML,
Pizzo SV,
Hill RL,
McKee PA.
Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248 (04) 1395-1407
33
Katona E,
Haramura G,
Kárpáti L,
Fachet J,
Muszbek L.
A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost 2000; 83 (02) 268-273
34
Schilling B,
Rardin MJ,
MacLean BX.
, et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics 2012; 11 (05) 202-214
36
Ridgway HJ,
Brennan SO,
Faed JM,
George PM.
Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98 (03) 632-639
37
Park R,
Doh HJ,
An SS,
Choi JR,
Chung KH,
Song KS.
A novel fibrinogen variant (fibrinogen Seoul II; AalphaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking. Blood 2006; 108 (06) 1919-1924
38
Hethershaw EL,
Cilia La Corte AL,
Duval C.
, et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12 (02) 197-205
44
Souri M,
Osaki T,
Ichinose A.
The non-catalytic B subunit of coagulation factor XIII accelerates fibrin cross-linking. J Biol Chem 2015; 290 (19) 12027-12039
46
Naski MC,
Lorand L,
Shafer JA.
Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. Biochemistry 1991; 30 (04) 934-941
47
Jacques SL,
LeMasurier M,
Sheridan PJ,
Seeley SK,
Kuliopulos A.
Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem 2000; 275 (52) 40671-40678
48
Ye J,
Liu LW,
Esmon CT,
Johnson AE.
The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J Biol Chem 1992; 267 (16) 11023-11028